LadRx Corp LADX
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if LADX is a good fit for your portfolio.
News
Trading Information
- Previous Close Price
- $2.42
- Day Range
- $2.47–2.50
- 52-Week Range
- $0.63–4.30
- Bid/Ask
- $2.48 / $2.99
- Market Cap
- $1.23 Mil
- Volume/Avg
- 1,882 / 800
Key Statistics
- Price/Earnings (Normalized)
- 0.70
- Price/Sales
- —
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- 20.36%
Company Profile
LadRx Corp operates as a biopharmaceutical research and development company in the healthcare sector of the United States. It is focused on the discovery, research, and clinical development of novel anti-cancer drug candidates that employ novel linker technologies to enhance the accumulation and release of cytotoxic anti-cancer agents at the tumor. The company develops Aldoxorubicin, which is meant to cure soft tissue sarcoma, a kind of tumor. It also develops Arimoclomol which is in development in Niemann Pick disease Type C (NPC) and Gaucher disease.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Core
- Total Number of Employees
- 2
- Website
- https://www.ladrxcorp.com
Valuation
|
Metric
|
LADX
|
|---|---|
Price/Earnings (Normalized) | 0.70 |
Price/Book Value | 3.56 |
Price/Sales | — |
Price/Cash Flow | 0.73 |
Price/Earnings
LADX
Financial Strength
|
Metric
|
LADX
|
|---|---|
Quick Ratio | 1.10 |
Current Ratio | 1.18 |
Interest Coverage | — |
Quick Ratio
LADX
Profitability
|
Metric
|
LADX
|
|---|---|
Return on Assets (Normalized) | −95.83% |
Return on Equity (Normalized) | −880.90% |
Return on Invested Capital (Normalized) | −502.06% |
Return on Assets
LADX
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Novo Nordisk A/S ADR
NVO
| Cmjyhwnqs | Ysxn | $565.6 Bil | |||
| Vertex Pharmaceuticals Inc
VRTX
| Kvknzgnxy | Lrvdxxh | $127.8 Bil | |||
| Regeneron Pharmaceuticals Inc
REGN
| Qdlwbptw | Bgcqhd | $118.7 Bil | |||
| Moderna Inc
MRNA
| Qpkywbhj | Kfhm | $46.8 Bil | |||
| Alnylam Pharmaceuticals Inc
ALNY
| Gdmsdlsj | Dbvsdhj | $29.7 Bil | |||
| argenx SE ADR
ARGX
| Lkljmfnj | Jqlr | $29.3 Bil | |||
| BioNTech SE ADR
BNTX
| Yhpdmfc | Rfps | $20.7 Bil | |||
| Biomarin Pharmaceutical Inc
BMRN
| Xcrmmbx | Wyxrrf | $16.1 Bil | |||
| United Therapeutics Corp
UTHR
| Lcqlldzz | Xqg | $15.0 Bil | |||
| Incyte Corp
INCY
| Qyztcjf | Phcwj | $13.5 Bil |